https://www.selleckchem.com/products/gw4869.html
%), or patient decision (6.5%). Predictors of discontinuation were higher HbA levels at baseline and use of basal insulin therapy before EOW treatment. EOW treatment, in a real-world setting, offers sustained and effective glycemic control and weight loss over 18 months in patients with T2DM. Diabetes duration and basal insulin therapy, however, may affect the outcome of EOW treatment, suggesting that early initiation of EOW could improve glycemic control and reduce the risk of treatment discontinuation. EOW treatment, in a real-world se
Aimer
Commentaire
Partagez
